Johnson & Johnson (NYSE:JNJ) on Friday announced a Phase 3 trial win for its anti-inflammatory therapy Tremfya, highlighting ...

Delays in diagnosing and treating psoriatic arthritis—a common inflammatory disorder affecting around 200,000 people in the U ...

While pharmacologic therapies remain central to managing PsO and PsA, non-pharmacologic interventions also play a crucial ...

Degenerative disc disease is common among young adults with PsA, with key risk factors including older age, male sex, diabetes, and inflammatory back pain.

Secukinumab treatment reduces bone erosion volume and enhances partial healing of erosions in patients with psoriatic ...

Department of Medicine, University of Toronto, Women's College Hospital, and co-authors have found biologics targeting ...

Johnson & Johnson's Phase 3b APEX study shows Tremfya reduces symptoms and structural damage in psoriatic arthritis patients ...

Based on clinical trial data, abatacept was not associated with increased malignancy risks in RA or PsA; observational data indicated a higher risk vs other b/tsDMARDs.

A new study explores gaps in how patients and physicians view psoriatic arthritis (PsA) and recommends ways for clinicians to ...

Psoriatic arthritis can affect any joint in the body, including the elbow. When joints are affected, symptoms may resemble other types of arthritis. Inflammatory arthritis happens when the immune ...

Many people associate psoriatic arthritis (PsA) with itchy, scaly skin and joint pain, but excess fatigue is also a symptom for at least 50% of people with PsA. Fatigue from PsA might be mild ...

Psoriatic arthritis (PsA) is a type of arthritis that often occurs along with the skin condition psoriasis. One common type is asymmetric oligoarticular PsA. Psoriatic arthritis (PsA) is a type of ...